IDO is the rate-limiting enzyme in the kynurenine pathway of tryptophan metabolism.
Abstract
IDO is the rate-limiting enzyme in the kynurenine pathway of tryptophan metabolism.
IDO activity is linked with immunosuppression by its ability to inhibit lymphocyte proliferation, and with neurotoxicity through generation of quinolinic acid and other toxins. IDO 
Introduction
The pathogenesis of HIV-1 infection is linked to dysfunction and depletion of CD4 + T lymphocytes [1] [2] [3] . Virus persists and disseminates over years, despite an apparently intact host immune system. The inability to eliminate HIV-1 suggests that negative-regulatory (tolerogenic) signals may shield HIV-1 from adaptive immune clearance 4,5 . However, the specific mechanisms by which the virus might protect itself from clearance remain unresolved.
HIV-1 is known to persist at low levels within the central nervous system (CNS) during most of the disease course 6 . Significant productive HIV-1 replication occurs in brain mononuclear phagocytes (MP; perivascular macrophages and microglia) during late stages of infection only in a subset of individuals with severe immune suppression and high peripheral viral loads. Secretory viral and cellular products from HIV-1 infected and immune competent brain MP are known to induce neuronal dysfunction and injury [7] [8] [9] .
These include virotoxins such as Tat, Nef and gp120 and cellular toxins such as proinflammatory cytokines, chemokines, arachidonic acid and its metabolites, platelet activating factor, nitric oxide and quinolinic acid. Indoleamine 2,3-dioxygenase (IDO) is the first and the rate-limiting enzyme in the generation of quinolinic acid from tryptophan via the kynurenine pathway 10 . An increase of functional IDO enzymatic activity in the brain could lead to enhanced production of neurotoxins resulting in neurocognitive dysfunction and HIV-1 associated dementia (HAD) [11] [12] [13] . Signs of increased IDO activity correlate with tryptophan depletion, progression of systemic and brain HIV-1 infection and HAD 14, 15 . Accumulating evidence suggests that IDO serves immunoregulatory and tolerogenic functions [16] [17] [18] [19] [20] [21] . From these data, it appears that certain antigen presenting cells 
Methods

Cell isolation and viral infection
Monocytes and PBL were obtained by countercurrent centrifugal elutriation of leukopheresis packs from HIV-1, 2 and hepatitis B seronegative donors. Monocytes were cultivated in suspension culture using Teflon flasks in Dulbecco's Modififed Eagle's Medium (DMEM, Sigma-Aldrich, St. Louis, MO) supplemented with 10% heatinactivated pooled human serum, 1% glutamine, 50 µg/ml gentamicin, 10 µg/ml ciprofloxacin (Sigma, St. Louis, MO), and 1000 U/ml highly purified recombinant human macrophage colony stimulating factor (a generous gift from Genetics Institute, Cambridge, MA). After seven days in culture, MDM were infected with HIV-1 ADA at multiplicity of infection of 0.01 31 .
Hu-PBL-NOD/SCID HIVE mice
Four-wk old male NOD/C.B-17 SCID mice were purchased (Jackson Laboratory, Bar
Harbor, ME Biomedical, Rockville, MD, USA). Similar amount of virus-specific antibodies were detected in control and 1-MT-treated animals (data not shown). 1-MT concentrations were detected in the brain tissue extracts by high performance liquid chromatography as described 19 . The average 1-MT peak values that could be detectable was 19.5 ± 2.23 µM.
The concentrations are 30% of ones seen in plasma of mice treated with 1-MT at similar dose. A total of three independent experiments were performed using three different human leukocyte donors. for later use. Coronal sections from the embedded blocks were cut in order to identify the injection site. For each mouse, 30-100 5-µm-thick serial sections were cut from the human MDM injection site and 3-7 slides (10 sections apart) were analyzed. Brain sections were deparaffinized with xylene and hydrated in gradient alcohols.
Immunohistochemical staining followed a basic indirect protocol, using antigen retrieval by heating to 95°C in 0.01mol/L citrate buffer for 30 min for antigen retrieval. To identify human cells in mouse brains, mAb to vimentin (1:50, clone 3B4, Dako Corporation, Carpenteria, CA), which identifies all human leukocytes was used 29 .
Human MDM and CD8 + lymphocytes were detected with CD68 (1:50 dilution, clone KP 
Human brain tissue
Frontal cortex and basal ganglia specimens (frozen and paraffin embedded) derived from eight HIVE cases of different severity (six severe and two mild according to previously described criteria 34 , six HIV-1 positive brains obtained from subjects without HIVE and five seronegative age-matched controls were used and provided by the National NeuroAIDS Consortium (Washington, DC) and the brain bank within the Center for
Neurovirology and Neurodegenerative Disorders (CNND). Approval was obtained from
the University of Nebraska Medical center institutional review board for these studies.
Serial paraffin sections (5-µm thickness) from basal ganglia and frontal cortex were immunostained for CD68, HIV-1 p24, CD8 and IDO as previously described. Double staining for CD8/IDO, CD68/IDO, CD68/HIV-1 p24 was performed as described 29 .
Numbers of CD8 + T lymphocytes were counted in blinded fashion in ten consecutive fields (objective x 20) in each brain section (basal ganglia and white matter of the frontal cortex).
Western blot assays
Western blot assays were performed on whole cell protein extracts of human brain homogenates (basal ganglia) and MDM cell extracts using primary Abs against CD68
(Dako), hu-IDO or -actin. Briefly, 10 µg of lysate protein was loaded onto 1.5 mm thick 
Statistic analysis
Data was analyzed using Prism (Graph Pad) with Student t-test for comparisons and ANOVA. P-values < 0.05 were considered significant. All results are presented as means ± standard error of the mean (SEM). (Figure 2A) . IDO expressing cells were predominantly CD68 + macrophages ( Figure 2B ) and microglia, and many of these cells were HIV-1 p24 antigen positive as seen in the microglial nodule ( Figure 2C ) and perivascular macrophages ( Figure 2D ). In addition, occasional IDO expressing astrocytes were seen in the shown). Table 2 shows results of two-color staining for human CD3 + CD4 + and CD8 + in peripheral blood samples 1-MT and vehicle-treated hu PBL NOD/SCID mice. At one wk the percentages of CD8 + (P < 0.001; 1-MT versus vehicle) and CD3 + T lymphocytes (P < 0.05; 1-MT versus vehicle) in the 1-MT group were significantly higher than in the control group. In contrast at wk 2 this was reversed. The control mice showed more CD8 + and CD3 + cells as compared to 1-MT mice (P < 0.05). The percentage of CD4 + T lymphocytes in peripheral blood was similar in both groups of animals 1 and 2 wks after MDM intracerebral injection. Similar levels of human lymphocytes (CD3 + , CD4 + , CD8 + ) were seen in peripheral blood at wk 3 in both groups ( Table 2) . HIV-1 p24 levels in peripheral blood of 1-MT treated mice were significantly lower than in the control animals (198±22.5 pg/ml versus 103±18.3 pg/ml, P < 0.02) at wk 2 (Table 2 ). This effect was not sustained at wk 3 when similar levels of HIV-1 p24 were found in blood (320±48.3 in control versus 328±63.22 pg/ml in 1-MT-treated animals).
Results
Accumulation and distribution of lymphocytes in HIVE brain tissue.
Abundant
As a measure of enhanced immune responses after IDO inhibition by 1-MT, we used IFN-intracellular staining of CD8 + T lymphocytes by flow cytometric analysis. Figure 3A shows two-color staining for CD8 + T lymphocyte versus IFN-expression in peripheral blood.
The 
Inhibition of IDO affects neuroinflammatory responses in hu-PBL NOD/SCID HIVE mice.
In order to analyze neuroinflammatory responses in the hu PBL NOD/SCID mice brains, 
CTL clearance of HIV-1 infected MDM in 1-MT treated hu-PBL-NOD/SCID HIVE mice.
Our previous studies indicated development of virus-specific CTL responses and partial elimination of HIV-1 infected MDM in the brains of hu-PBL-NOD-SCID mice with HIVE 29 . In order to test the effect of IDO inhibition on eradication of virus-infected macrophages, CD68 + , HIV-1 p24 + and CD8 + T lymphocytes were counted in brain tissue in blind fashion by two observers. Mean numbers of stained cells per section within the injected hemisphere were calculated for each mouse (three sections/mouse) and mean numbers of cells for 6-8 mice per treatment group were evaluated at weeks 2 and 3 after MDM injection. Table 3 shows that IDO serves as a negative regulator of the immune system. IDO activity in APCs is a potent mechanism for inducing immunosuppression and tolerance. Expression of IDO allows professional APCs (macrophages and dendritic cells) to inhibit T lymphocyte activity in vitro 19, 20, 37 . IDO contributes to T cell tolerance of the fetus during gestation 38 and suppresses autoimmunity in a variety of animal models [39] [40] [41] [42] . The IDO pathway is believed to confer a 43 ] . However, given that IDO is up-regulated in HIV-1 infected macrophages 35 , we hypothesized that the in vivo immunosuppressive properties of IDO might confer an advantage to HIV-1 by allowing the virus to escape CTL clearance.
The antigen specific CD8 + T lymphocytes serve a prominent role in the control of HIV-1 infection in both brain and peripheral tissues [44] [45] [46] . In our prior studies using a murine model for Current study presents clear indication of increased infiltration of CD8 + T lymphocytes in HIVE. Similar distribution of CD8 + lymphocytes (followed virus-infected cells in antigenspecific manner) was recently described in SIV encephalitis by Kim and colleagues 47 . These observations are consistent with previous report demonstrating that HIV-1 infected macrophages attract lymphocytes 46 and serve as APCs 48, 49 . Two studies showed that IDO mRNA is high in However, little is known about the source and sites of IDO expression in humans with HIVE.
Our findings that perivascular macrophages and microglial nodules are the source of IDO production in the brains of HIVE patients are in concordance with reports on the source of IDO we show in the present study, these T cells are also capable of progressively clearing the HIV-1-infected macrophages from the brain, as long as IDO is inhibited.
HIV-1 infected MDM may serve as a stable reservoir for virus in the brain. Based on our data and the growing literature, we hypothesize that this reservoir is accessible to the immune system and triggers an immune response, but it is resistant to clearance due to the immunosuppressive effects of IDO. This idea potentially has direct clinical relevance, because 1-MT, the pharmacological inhibitor of IDO utilized to inhibit IDO activity in vivo 30, 38 , and it is now in preclinical development as an immunomodulatory drug. Interestingly, no toxic effect of increased CD8 + T lymphocyte infiltration was seen in our study (as evidenced by quantitative assessment of microglial reaction). For personal use only. on . by guest www.bloodjournal.org From
Figure 1
For personal use only. on April 21, 2017. by guest www.bloodjournal.org From
39
Figure 2
For personal use only. on . by guest www.bloodjournal.org From
40
Figure 3
41
Figure 4
42
Figure 5
